Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 380 | 79 | 300 |
| Samples | 256 | 60 | 195 |
| Peptides | 188 | 33 | 161 |
Function
PGC · Progastricsin
This gene encodes an aspartic proteinase that belongs to the peptidase family A1. The encoded protein is a digestive enzyme that is produced in the stomach and constitutes a major component of the gastric mucosa. This protein is also secreted into the serum. This protein is synthesized as an inactive zymogen that includes a highly basic prosegment. This enzyme is converted into its active mature form at low pH by sequential cleavage of the prosegment that is carried out by the enzyme itself. Polymorphisms in this gene are associated with susceptibility to gastric cancers. Serum levels of this enzyme are used as a biomarker for certain gastric diseases including Helicobacter pylori related gastritis. Alternate splicing results in multiple transcript variants. A pseudogene of this gene is found on chromosome 1. [provided by RefSeq, Oct 2009].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 166 amino-acid changes on canonical ENST00000373025 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PGC · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PGC – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 8/210 4% | 44/1899 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Endometrial Carcinoma | 0/42 0% | 9/612 1% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Non-Small Cell Lung Carcinoma | 16/304 5% | 6/1390 0% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Colorectal Carcinoma | 13/143 9% | 23/3239 1% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Other Solid Cancers | 1/94 1% | 14/1515 1% |
| Ovarian Carcinoma | 1/109 1% | 8/998 1% |
| Bladder Carcinoma | 0/58 0% | 7/956 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Gastric Carcinoma | 0/74 0% | 10/1809 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 3/810 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 12/2550 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Hepatocellular Carcinoma | 0/46 0% | 8/2210 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| B-Lymphoblastic Leukemia | 4/55 7% | 3/2640 0% |
| Prostate Carcinoma | 2/13 15% | 3/2105 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Kidney Carcinoma | 0/85 0% | 4/1862 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
Mutation Distribution
Where PGC is mutated · all tissues, split by cell line vs tissue
How many mutations in PGC were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 380 mutations in PGC
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|